GlobeImmune, Inc.
GBIM
$0.0002
$0.000.00%
OTC PK
| 03/31/2016 | 12/31/2015 | 09/30/2015 | 06/30/2015 | 03/31/2015 | |
|---|---|---|---|---|---|
| Revenue | 8.31% | 8.23% | -62.16% | -72.65% | -73.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.31% | 8.23% | -62.16% | -72.65% | -73.69% |
| Cost of Revenue | -59.28% | -46.96% | -32.11% | -30.37% | -26.40% |
| Gross Profit | 557.53% | 291.05% | -74.58% | -92.91% | -95.77% |
| SG&A Expenses | -3.63% | 6.48% | 24.52% | 33.02% | 29.07% |
| Depreciation & Amortization | -58.13% | -36.55% | -27.71% | -36.82% | -51.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.47% | -21.73% | -12.15% | -10.22% | -10.33% |
| Operating Income | 66.50% | 52.45% | -157.37% | -193.26% | -172.46% |
| Income Before Tax | 86.55% | 82.99% | 0.98% | -675.83% | -276.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.55% | 82.99% | 3.95% | -713.10% | -279.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.55% | 82.99% | 3.95% | -713.10% | -279.14% |
| EBIT | 66.50% | 52.45% | -157.37% | -193.26% | -172.46% |
| EBITDA | 66.93% | 53.30% | -150.75% | -182.71% | -164.21% |
| EPS Basic | 99.62% | 99.70% | 99.17% | 98.33% | -95.35% |
| Normalized Basic EPS | 99.39% | 99.43% | -102.08% | -104.80% | -163.72% |
| EPS Diluted | 99.59% | 99.68% | 99.14% | 98.33% | -95.35% |
| Normalized Diluted EPS | 99.34% | 99.40% | -102.18% | -104.80% | -163.72% |
| Average Basic Shares Outstanding | 33.32% | 98.37% | 289.76% | 5,984.97% | 4,553.83% |
| Average Diluted Shares Outstanding | 40.24% | 108.67% | 309.97% | 5,984.97% | 4,553.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |